Genscript Biotech Corp Class H GNNSF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $5.20
- Day Range
- $5.50–5.50
- 52-Week Range
- $1.30–6.55
- Bid/Ask
- $1.10 / $20,453.50
- Shares Outstanding
- 2.28B
- Market Cap
- $12.02B
- Volume/Avg
- 153 / 2,492
Key Statistics
- Price/Earnings (Normalized)
- 48.64
- Price/Sales
- 13.57
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 6,135
- Website
- https://www.genscript.com
Valuation
|
Metric
|
GNNSF
|
|---|---|
Price/Earnings (Normalized) | 48.64 |
Price/Book Value | 3.07 |
Price/Sales | 13.57 |
Price/Cash Flow | 61.50 |
Price/Earnings
GNNSF
Financial Strength
|
Metric
|
GNNSF
|
|---|---|
Quick Ratio | 1.39 |
Current Ratio | 1.53 |
Interest Coverage | −41.48 |
Quick Ratio
GNNSF
Profitability
|
Metric
|
GNNSF
|
|---|---|
Return on Assets (Normalized) | 2.29% |
Return on Equity (Normalized) | 2.92% |
Return on Invested Capital (Normalized) | 2.40% |
Return on Assets
GNNSF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|nGq#^M | LOCK|Kh$$D | $129B | |||
| Moderna Inc
MRNA
| LOCK|B!rSPb | LOCK|qL# | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|VK>$&<g | LOCK|mmyf | $77B | |||
| argenx SE ADR
ARGX
| LOCK|^<&bGj | LOCK|?^l | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$YP<&WZ | LOCK|GS | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|D^Tlg% | LOCK|rXCX | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|qWjTF<zh | LOCK|HBS@ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Bh$DvY | LOCK|crH | $24B | |||
| Incyte Corp
INCY
| LOCK|@<XTFG | LOCK|J% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|T%V&xw | LOCK|F$ | $14B |
United States